NKp30/NCR3 Antibody (C1)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-41508

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-41508
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # C1

Concentration

1 mg/ml

View all NKp30/NCR3 Antibodies »

Product Specifications

Immunogen

Immunized with recombinant Human NKp30/NCR3 (Uniprot#: O14931; Ser22-Gly135 (Uniprot#: O14931)

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Applications for NKp30/NCR3 Antibody (C1)

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

5-20ug/mL

Immunohistochemistry

5-20ug/mL

Western Blot

0.5-2ug/mL

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS, pH7.4, 50% glycerol

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: NKp30/NCR3

NKp30, also referred to as natural cytotoxicity receptor 3 (NCR3), is a type I transmembrane receptor belonging to the immunoglobulin (Ig) superfamily that is expressed on resting and active natural killer (NK) cells with a role in triggering a cytotoxic response against tumor cells (1). The human NKp30 protein has six isoforms. The canonical isoform (NKp30a) is 177 amino acids (aa) in length with a theoretical molecular weight of 21.6 kDa (1,2). The NKp30 protein consists of a signal peptide, an Ig domain, a stalk region, a transmembrane domain, and an intracellular region (1-3). NKp30/NCR3 signaling relies on interaction with the immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor molecules CD3zeta and FcRgamma (1,4,5). Other NRC family members include NKp44 and NKp46 (1,3-6). NK cell activation and tumor surveillance occurs through receptor-ligand binding. Tumor-derived ligands for NKp30 include HLA-B-associated transcript 3 (BAT3)/Bcl2-associated anthogene 6 (BAG6) and B7-H6 (4-6). NKp30 has also been suggested to play a role in NK-dendritic cell (DC) crosstalk by promoting DC maturation and cytotoxicity of immature DCs, mediated in part by BAT3 (1,4,5).

Given its role in NK cell-mediated killing and activation, NKp30 is a potential target for cancer immunotherapies (6). For instance, Bi-specific T cell engagers (BiTE) is one immunotherapy approach targeting the NKp30/B7-H6 interaction where B7-H6-specific BiTE elicits an attack on tumor cells through interferon gamma (IFNgamma) production and T cell cytotoxicity (1). Another potential approach is NKp30-derived chimeric antigen receptors (CARs) where CAR-T cells that express chimeric NKp30 receptors can efficiently attack B7-H6 tumor cells (1,6).

References

1. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The natural cytotoxicity receptors in health and disease. Frontiers in Immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909

2. Uniprot (O14931)

3. Luczo, J. M., Ronzulli, S. L., & Tompkins, S. M. (2021). Influenza A virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30. Viruses, 13(2), 156. https://doi.org/10.3390/v13020156

4. Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., & Campbell, K. S. (2017). Regulation of the Functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression. Frontiers in Immunology, 8, 369.

5. Kaifu, T., Escaliere, B., Gastinel, L. N., Vivier, E., & Baratin, M. (2011). B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and Molecular Life Sciences : CMLS, 68(21), 3531-3539. https://doi.org/10.1007/s00018-011-0802-7

6. Pinheiro, P. F., Justino, G. C., & Marques, M. M. (2020). NKp30 - A prospective target for new cancer immunotherapy strategies. British Journal of Pharmacology, 177(20), 4563-4580. https://doi.org/10.1111/bph.15222

Alternate Names

CD337, NCR3

Gene Symbol

NCR3

Additional NKp30/NCR3 Products

Product Documents for NKp30/NCR3 Antibody (C1)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for NKp30/NCR3 Antibody (C1)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.